Shattuck Labs, Inc. (STTK) – What Are Researchers Saying About This Stock?

Shattuck Labs, Inc. (NASDAQ:STTK) has earned an average recommendation of “Buy” from the thirteen ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, nine have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $13.70.

Several equities research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Shattuck Labs in a research note on Friday, September 11th. Needham & Company LLC increased their target price on shares of Shattuck Labs from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, October 2nd. Raymond James Financial reissued a “strong-buy” rating on shares of Shattuck Labs in a research report on Thursday, November 5th. Leerink Partners assumed coverage on shares of Shattuck Labs in a research note on Monday, July 20th. They issued an “outperform” rating and a $16.00 price target for the company. Finally, JPMorgan Chase & Co. started coverage on shares of Shattuck Labs in a research note on Friday, July 24th. They issued an “overweight” rating and a $10.00 price target for the company.

Shattuck Labs Stock Performance

Shares of STTK traded down $0.16 during mid-day trading on Friday, hitting $4.65. 775,897 shares of the company’s stock were exchanged, compared to its average volume of 964,645. The company has a market cap of $473.56 million, a price-to-earnings ratio of -9.12 and a beta of 1.21. Shattuck Labs has a fifty-two week low of $1.72 and a fifty-two week high of $8.33. The stock’s 50-day moving average is $5.80 and its 200-day moving average is $6.04.

Shattuck Labs (NASDAQ:STTK) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). As a group, equities research analysts anticipate that Shattuck Labs will post -0.51 EPS for the current year.

Institutional Trading of Shattuck Labs

Several hedge funds have recently modified their holdings of the stock. Empowered Funds LLC purchased a new position in Shattuck Labs in the third quarter valued at $284,000. State Street Corp increased its holdings in Shattuck Labs by 67.4% during the 3rd quarter. State Street Corp now owns 3,435,783 shares of the company’s stock worth $23,432,000 after purchasing an additional 1,382,995 shares during the period. Voya Investment Management LLC increased its holdings in Shattuck Labs by 30.7% during the 3rd quarter. Voya Investment Management LLC now owns 15,389 shares of the company’s stock worth $105,000 after purchasing an additional 3,611 shares during the period. Fisher Asset Management LLC acquired a new stake in Shattuck Labs in the 3rd quarter valued at about $575,000. Finally, Profund Advisors LLC acquired a new stake in Shattuck Labs in the 3rd quarter valued at about $195,000. 58.74% of the stock is currently owned by institutional investors and hedge funds.

About Shattuck Labs

Shattuck Labs, Inc. is a clinical-stage biotechnology company developing medicines that modulate the immune system to treat cancer. The company’s research has centered on biologic therapies designed to combine immune checkpoint inhibition with activation of immune cells. Its lead candidate, SL-172154, is an engineered fusion protein designed to block the CD47 “don’t eat me” signal and activate CD40, with the aim of promoting an antitumor immune response. Shattuck has evaluated the candidate in clinical studies for cancers including ovarian cancer and higher-risk myelodysplastic syndromes.